Healthcare
This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term-care facilities, and medical equipment and supplies. Also include pharmaceutical retailers and companies which provide health information services. Companies in this sector include AstraZeneca, Pfizer, and Roche Holding, Walgreens Boots Alliance, and Cerner Corp.
Market Cap
6.987T
Market Weight
8.62%
Industries
11
Companies
1148
Healthcare
S&P 500 ^GSPC
Loading chart for Healthcare
Day Return
Sector
2.13%
S&P 500
0.29%
YTD Return
Sector
3.45%
S&P 500
4.84%
1-Year Return
Sector
11.44%
S&P 500
29.83%
3-Year Return
Sector
11.54%
S&P 500
73.41%
5-Year Return
Sector
12.18%
S&P 500
72.45%
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
Industry
Market Weight
YTD Return
All Industries
-3.45%
Drug Manufacturers - General
5.09%
Biotechnology
3.03%
Medical Devices
-18.41%
Healthcare Plans
8.67%
Diagnostics & Research
-20.48%
Medical Instruments & Supplies
-17.04%
Medical Distribution
-2.62%
Medical Care Facilities
-3.39%
Drug Manufacturers - Specialty & Generic
0.85%
Health Information Services
-33.91%
Pharmaceutical Retailers
-27.12%
Note: Percentage % data on heatmap indicates Day Return
All Industries
--
Day Return
--
Market Weight
--
YTD Return
--
Drug Manufacturers - General
-3.75%
Biotechnology
-1.71%
Medical Devices
-1.10%
Healthcare Plans
+0.55%
Diagnostics & Research
-2.70%
Medical Instruments & Supplies
-1.37%
Medical Distribution
+2.03%
Medical Care Facilities
+0.94%
Drug Manufacturers - Specialty & Generic
-1.68%
Health Information Services
+0.53%
<= -3
-2
-1
0
1
2
>= 3
Largest Companies in This Sector
View More| Name
|
Last Price
|
1Y Target Est.
|
Market Weight
|
Market Cap
|
Day Change %
|
YTD Return
|
Avg. Analyst Rating
|
|---|---|---|---|---|---|---|---|
| 963.33 | 1,198.41 | 12.74% | 862.006B | +3.07% | -10.36% | Buy
|
|
| 227.19 | 252.42 | 8.08% | 546.896B | -1.16% | +9.78% | Buy
|
|
| 206.60 | 250.03 | 5.40% | 365.426B | -2.23% | -9.58% | Buy
|
|
| 368.78 | 387.27 | 4.95% | 334.931B | -0.46% | +11.71% | Buy
|
|
| 112.16 | 129.59 | 4.10% | 277.022B | +2.73% | +6.56% | Buy
|
|
| 329.82 | 353.33 | 2.63% | 177.999B | -4.75% | +0.77% | Hold
|
|
| 469.21 | 620.12 | 2.58% | 174.368B | -2.04% | -19.02% | Strong Buy
|
|
| 131.65 | 158.36 | 2.42% | 163.404B | +0.62% | +7.26% | Buy
|
|
| 457.78 | 577.01 | 2.40% | 162.129B | +0.04% | -19.17% | Buy
|
|
| 89.46 | 118.64 | 2.30% | 155.823B | -1.46% | -28.60% | Buy
|
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
View More| Name
|
Last Price
|
Net Assets
|
Expense Ratio
|
YTD Return
|
|---|---|---|---|---|
| 145.16 | 38.604B | 0.08% | -6.23% | |
| 271.31 | 18.588B | 0.09% | -5.75% | |
| 167.27 | 8.123B | 0.44% | -0.89% | |
| 130.42 | 7.434B | 0.35% | +6.96% | |
| 92.41 | 3.624B | 0.40% | -5.12% |
Mutual Fund Opportunities
View More| Name
|
Last Price
|
Net Assets
|
Expense Ratio
|
YTD Return
|
|---|---|---|---|---|
| 189.63 | 37.212B | 0.32% | -7.30% | |
| 79.95 | 37.212B | 0.32% | -7.30% | |
| 135.75 | 18.588B | 0.09% | -5.69% | |
| 123.14 | 14.705B | 0.00% | -7.56% | |
| 10.24 | 14.705B | 0.00% | -7.79% |
Healthcare Research
View MoreDiscover the Latest Analyst and Technical Research for This Sector
-
Analyst Report: DexCom, Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
RatingPrice Target -
Analyst Report: Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
RatingPrice Target -
Analyst Report: Moderna, Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
RatingPrice Target -
Analyst Report: Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam’s commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
RatingPrice Target
